A combination of in vitro and in vivo models with validation in human tumors has identified AXL activation as a new mechanism of acquired resistance to EGFR inhibitors in non–small cell lung cancer. The identification of this mechanism, alongside the current development of specific AXL inhibitors, provides the rationale for further studies that may improve treatment for EGFR inhibitor–resistant patients.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities
Molecular Cancer Open Access 19 February 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Lynch, T.J. et al. N. Engl. J. Med. 350, 2129–2139 (2004).
Paez, J.G. et al. Science 304, 1497–1500 (2004).
Pao, W. et al. Proc. Natl. Acad. Sci. USA 101, 13306–13311 (2004).
Sequist, L.V. et al. Sci. Transl. Med. 3, 75ra26 (2011).
Oxnard, G.R. et al. Clin. Cancer Res. 17, 1616–1622 (2011).
Zhang, Z. et al. Nat. Genet. 44, 852–860 (2012).
Verma, A., Warner, S.L., Vankayalapati, H., Bearss, D.J. & Sharma, S. Mol. Cancer Ther. 10, 1763–1773 (2011).
Linger, R.M., Keating, A.K., Earp, H.S. & Graham, D.K. Expert Opin. Ther. Targets 14, 1073–1090 (2010).
Ye, X. et al. Oncogene 29, 5254–5264 (2010).
Imai, K. & Takaoka, A. Nat. Rev. Cancer 6, 714–727 (2006).
Jackman, D. et al. J. Clin. Oncol. 28, 357–360 (2010).
Chaft, J.E. et al. Clin. Cancer Res. 17, 6298–6303 (2011).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Postel-Vinay, S., Ashworth, A. AXL and acquired resistance to EGFR inhibitors. Nat Genet 44, 835–836 (2012). https://doi.org/10.1038/ng.2362
Published:
Issue Date:
DOI: https://doi.org/10.1038/ng.2362
This article is cited by
-
Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities
Molecular Cancer (2018)
-
Dual gene activation and knockout screen reveals directional dependencies in genetic networks
Nature Biotechnology (2018)
-
Kinase inhibitors: the road ahead
Nature Reviews Drug Discovery (2018)
-
Heterozygous Mutations in AAGAB Cause Type 1 Punctate Palmoplantar Keratoderma with Evidence for Increased Growth Factor Signaling
Journal of Investigative Dermatology (2013)